NC-LENOVO
8.9.2021 06:02:11 CEST | Business Wire | Press release
Today, at its annual Tech World event, Lenovo announced an evolution in its consumption-based business model, introducing Lenovo TruScale , a new portfolio-spanning everything-as-a-service offering. This announcement is part of Lenovo’s continuing transformation for the next reality – a new era where consumers and business leaders need new solutions and technologies to face unprecedented change in business, education, living and beyond.
Expanding its TruScale brand beyond infrastructure services, Lenovo is bringing all of its as-a-service offerings under one umbrella to provide a truly global solution that makes everything from the pocket to the cloud available via a single contract framework. Lenovo TruScale embodies the company’s vision and transformation for the next reality – meeting the growing global demand for smarter technology amid a new era of hybrid working and learning.
“Digital transformation is accelerating faster than ever, and companies are struggling to keep pace with the speed of innovation. We hear from CIOs every day that their organizations’ technology needs are evolving every 12-18 months,” said Ken Wong, president of Solutions & Services Group. “With Lenovo TruScale, customers can expect one solution, one provider, one contract framework, and a single point of accountability for everything-as-a-service.”
Lenovo TruScale offers businesses of all sizes an everything-as-a-service platform with the flexibility they need to stay competitive with a scalable, cloud-like consumption model and predictable payment options for hardware and service inclusions. This transition to a fully integrated as-a-service strategy brings to life the company’s “One Lenovo” vision – addressing common business challenges and providing IT leaders with the performance and flexibility to pay-as-you-grow. With Lenovo TruScale, IT leaders’ infrastructure solutions are fully managed, giving customers the advantages of an on-premise cloud environment along with the peace of mind around data management in a hybrid environment.
Research shows the as-a-service market is growing at four times the overall IT services total addressable market. In three years, as-a-service models will represent 12% of enterprise x86 server spend and over 50% of new enterprise storage spend, growing at 40% CAGR and around 17% of commercial PC spend, up from 1% two years ago and growing at 50% CAGR.1
As the world shifts to a flexible “work, learn and connect-from-anywhere” model, organizations that embrace smarter technology designed for a hybrid reality will benefit from this transition. This requires flexibility in devices and work platforms, on-demand support when and where needed, and customizable solutions across the organization, benefits that many will recognize from Lenovo’s existing Device-as-a-Service solution. Now moving under the new TruScale umbrella, Lenovo DaaS will continue to help customers move to a Modern IT environment by combining the best end-to-end technology from across Lenovo with lifecycle services and support and convenient financing to deliver lower total cost of ownership.
Lenovo is building a new way to deliver as-a-service to the market and offer organizations ultimate flexibility in how they leverage their IT infrastructure, services and software. By forming strategic alliances with other market leaders, customers can get the public cloud experience with the security and control of an on-premises solution. As part of this new platform, Lenovo has joined with leading infrastructure partners Deloitte, VMWare and Intel, and DaaS security partners Absolute Software and SentinelOne to provide organizations with various dynamic offerings such as hybrid cloud solutions for Edge to Cloud environments, best-in-class managed security solutions and access to the most current storage infrastructure innovation, for the life of their data, with the ability to scale storage capacity on demand.
“Lenovo’s as-a-service approach helps meet the market's demand for responsive, reliable hybrid cloud operations. Put simply our organizations are helping companies grow their enterprises and mitigate risks to create more value and serve society better,” said Punit Renjen, CEO of Deloitte Global.
Learn more about TruScale’s latest offerings at Lenovo’s annual global innovation event, Tech World .
1 Gartner, IDC, Lenovo Market Intelligence
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005942/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
